Actively Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Led by AstraZeneca · Updated on 2026-03-24
257
Participants Needed
59
Research Sites
223 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.
CONDITIONS
Official Title
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at the time of signing consent.
- Able to provide a tumor sample for PD-L1 testing if applicable.
- ECOG performance status of 0 or 1.
- Measurable disease according to RECIST 1.1 or its variations.
- Life expectancy of at least 12 weeks.
- Adequate organ and bone marrow function.
- Body weight greater than 35 kg.
- Capable of giving informed consent.
You will not qualify if you...
- Spinal cord compression.
- Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 14 days before treatment start (sub-studies 1-4).
- Untreated or progressive brain metastases (sub-study 5).
- For sub-studies 1-3, exclusion of primary neuroendocrine, mesenchymal, sarcomatoid, or other non-included histologies.
- Not recovered to baseline or Grade 1 or less from side effects of prior anti-cancer therapy.
- Radiotherapy within 2 weeks before enrollment (sub-study 2).
- Contraindications to 5-FU, paclitaxel, or carboplatin (sub-studies 3 and 4).
- History of another primary malignancy except specific treated and low-risk cases.
- History or evidence of organ or stem cell transplant.
- Active infections including uncontrolled HIV, hepatitis B or C, or active hepatitis A.
- History of active primary immunodeficiency or autoimmune/inflammatory disorders.
- Candidates for curative therapy.
- Prior immune-mediated therapy exposure.
- Current or recent use of immunosuppressive drugs within 14 days before first study dose, except specific steroid uses.
- Any anti-cancer therapy within 28 days or 5 half-lives before first dose (sub-studies 1-4).
- Concurrent chemotherapy except study drugs, radiotherapy, investigational, biologic, or hormonal cancer therapy.
- Radiotherapy to large bone marrow areas within 4 weeks before first dose.
- Major surgery within 4 weeks before first dose or still recovering.
- Live attenuated vaccine within 30 days before first dose.
- Known allergy or hypersensitivity to study treatments or their ingredients.
- For sub-study 5, prior systemic therapy, non-palliative radiotherapy, or radical pleuropneumonectomy for mesothelioma.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 59 locations
1
Research Site
Los Angeles, California, United States, 90025
Withdrawn
2
Research Site
Baltimore, Maryland, United States, 21201
Not Yet Recruiting
3
Research Site
Stony Brook, New York, United States, 11794
Not Yet Recruiting
4
Research Site
Columbus, Ohio, United States, 43210
Not Yet Recruiting
5
Research Site
Ijuí, Brazil, 98700-000
Actively Recruiting
6
Research Site
Londrina, Brazil, 86015-520
Actively Recruiting
7
Research Site
São Caetano do Sul, Brazil, 09541-270
Actively Recruiting
8
Research Site
Vitória, Brazil, 29043-260
Actively Recruiting
9
Research Site
Anyang, China, 455000
Not Yet Recruiting
10
Research Site
Beijing, China, 100142
Not Yet Recruiting
11
Research Site
Beijing, China, 100730
Active, Not Recruiting
12
Research Site
Beijing, China, 100730
Actively Recruiting
13
Research Site
Beijing, China, CN-100730
Actively Recruiting
14
Research Site
Bengbu, China, 233004
Withdrawn
15
Research Site
Changchun, China, 130021
Withdrawn
16
Research Site
Changchun, China, 130021
Not Yet Recruiting
17
Research Site
Changsha, China, 410003
Actively Recruiting
18
Research Site
Changsha, China, 410008
Active, Not Recruiting
19
Research Site
Changsha, China, 410008
Actively Recruiting
20
Research Site
Changsha, China, 410013
Completed
21
Research Site
Chengdu, China, 610041
Active, Not Recruiting
22
Research Site
Chengdu, China, 610072
Actively Recruiting
23
Research Site
Chongqing, China, 400030
Actively Recruiting
24
Research Site
Chongqing, China, 400030
Withdrawn
25
Research Site
Dongguan, China, 523009
Active, Not Recruiting
26
Research Site
Dongguan, China, 523009
Actively Recruiting
27
Research Site
Fuzhou, China, 350011
Completed
28
Research Site
Fuzhou, China, 350014
Not Yet Recruiting
29
Research Site
Hangzhou, China, 310022
Active, Not Recruiting
30
Research Site
Hangzhou, China, 310022
Actively Recruiting
31
Research Site
Hefei, China, 230031
Withdrawn
32
Research Site
Jining, China, 272029
Actively Recruiting
33
Research Site
Kunming, China, 650118
Actively Recruiting
34
Research Site
Nanchang, China, 330006
Actively Recruiting
35
Research Site
Nanjing, China, 210009
Not Yet Recruiting
36
Research Site
Nanning, China, 530021
Active, Not Recruiting
37
Research Site
Nanning, China, 530021
Actively Recruiting
38
Research Site
Shandong, China, 250117
Actively Recruiting
39
Research Site
Shandong, China
Actively Recruiting
40
Research Site
Shandong, China
Active, Not Recruiting
41
Research Site
Shandong, China
Not Yet Recruiting
42
Research Site
Shanghai, China, 200120
Active, Not Recruiting
43
Research Site
Shanghai, China, 200120
Actively Recruiting
44
Research Site
Shenyang, China, 110004
Actively Recruiting
45
Research Site
Tianjin, China, 300060
Active, Not Recruiting
46
Research Site
Tianjin, China, 300060
Actively Recruiting
47
Research Site
Wuhan, China, 430022
Actively Recruiting
48
Research Site
Wuhan, China, 430022
Active, Not Recruiting
49
Research Site
Wuhan, China, 430030
Actively Recruiting
50
Research Site
Wuhan, China, 430040
Actively Recruiting
51
Research Site
Wuhan, China, 430079
Actively Recruiting
52
Research Site
Wuhou District, China, 610041
Actively Recruiting
53
Research Site
Zhengzhou, China, 450008
Not Yet Recruiting
54
Research Site
Namdong-gu, South Korea, 21565
Actively Recruiting
55
Research Site
Seoul, South Korea, 03722
Actively Recruiting
56
Research Site
Taichung, Taiwan
Not Yet Recruiting
57
Research Site
Taipei, Taiwan, 112
Actively Recruiting
58
Research Site
Hanoi, Vietnam, 100000
Actively Recruiting
59
Research Site
Ho Chi Minh City, Vietnam, 700000
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
8
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here